Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Dual-burst Xanomeline (KarXT + KarX-EC) vs KarXT in Healthy Japanese Adults and Elderly
NCT06605950Phase 1Completed
- Sponsor
- Karuna Therapeutics
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of xanomeline and trospium in schizophrenia and Alzheimer's disease (AD) (4 arms), sponsored by Karuna Therapeutics. Primary endpoints: Number of participants with Adverse Events, Number of participants with Serious Adverse Events and 6 more. Started Oct 2024; status: completed.
02
Drugs
xanomelinetrospium
03
Conditions
schizophreniaAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06605950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06605950.